Catalyst Event
Abbott Laboratories (ABT) · Earnings Release
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
4/16/2026, 12:00:00 AM
Abbott announced Q1 2026 results, beating revenue estimates but lowering its full-year 2026 adjusted EPS forecast to $5.38-$5.58, citing $0.20 of dilution from the Exact Sciences acquisition.
Korean Translation
애보트, 2026년 1분기 실적 발표. 매출은 예상을 상회했으나 Exact Sciences 인수 관련 희석 효과 0.20달러를 이유로 2026년 연간 조정 EPS 전망치를 5.38-5.58달러로 하향 조정함.
Related Recent Events
Novo Nordisk A/S (NVO) · Earnings Release
Novo Nordisk is scheduled to release its Q1 2026 earnings report before the market opens on May 6, 2026, with high importance estimated due to potential 10% price impact, expected.
5/6/2026, 12:00:00 AM
Life Time Group Holdings Inc (LTH) · Earnings Release
Life Time Group Holdings is scheduled to report its Q1 2026 financial results. A moderate market reaction is estimated for this standard earnings release scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Eli Lilly is scheduled to announce its first-quarter 2026 financial results on April 30, 2026, followed by a conference call. High impact is estimated due to significant market focus on GLP-1 sales growth scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is scheduled to release its Q1 2026 earnings on April 30, 2026; impact is estimated as neutral pending the actual report, scheduled.
4/30/2026, 12:00:00 AM
Amgen Inc (AMGN) · Earnings Release
Amgen is expected to report its Q1 2026 financial results after the market closes on April 30, 2026, scheduled. Analysts estimate a Low impact (~1-2%) as a standard scheduled reporting event, scheduled.
4/30/2026, 12:00:00 AM
Astrazeneca PLC (AZN) · Earnings Release
AstraZeneca's Q1 2026 results announcement is scheduled for April 29, 2026 scheduled
4/29/2026, 12:00:00 AM